Share Email Print

Proceedings Paper

Early identification of non-responding locally advanced breast tumors receiving neoadjuvant chemotherapy
Author(s): Martijn Van de Giessen; Boudewijn E. Schaafsma; Ayoub Charehbili; Vincent T. H. B. M. Smit; Judith R. Kroep; Boudewijn P. F. Lelieveldt; Gerrit-Jan Liefers; Alan Chan; Clemens W. G. M. Löwik; Jouke Dijkstra; Cornelis J. H. van de Velde; Martin N. J. M. Wasser; Alexander L. Vahrmeijer
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Diffuse optical spectroscopy (DOS) may be advantageous for monitoring tumor response during chemotherapy treatment, particularly in the early treatment stages. In this paper we perform a second analysis on the data of a clinical trial with 25 breast cancer patients that received neoadjuvant chemotherapy. Patients were monitored using delayed contrast enhanced MRI and additionally with diffuse optical spectroscopy at baseline, after 1 cycle of chemotherapy, halfway therapy and before surgery.

In this analysis hemoglobin content between tumor tissue and healthy tissue of the same breast is compared on all four monitoring time points. Furthermore, the predictive power of the tumor-healthy tissue difference of HbO2 for non-responder prediction is assessed.

The difference in HbO2 content between tumor and healthy tissue was statistically significantly higher in responding tumors than in non-responding tumors at baseline (10.88 vs -0.57 μM, P=0.014) and after one cycle of chemotherapy (6.45 vs -1.31 μM, P=0.048). Before surgery this difference had diminished. In the data of this study, classification on the HbO2 difference between tumor and healthy tissue was able to predict tumor (non-)response at baseline and after 1 cycle with an area-under-curve of 0.95 and 0.88, respectively.

While this result suggests that tumor response can be predicted before chemotherapy onset, one should be very careful with interpreting these results. A larger patient population is needed to confirm this finding.

Paper Details

Date Published: 26 February 2015
PDF: 7 pages
Proc. SPIE 9303, Photonic Therapeutics and Diagnostics XI, 93032K (26 February 2015); doi: 10.1117/12.2078845
Show Author Affiliations
Martijn Van de Giessen, Leiden Univ. Medical Ctr. (Netherlands)
Boudewijn E. Schaafsma, Leiden Univ. Medical Ctr. (Netherlands)
Ayoub Charehbili, Leiden Univ. Medical Ctr. (Netherlands)
Vincent T. H. B. M. Smit, Leiden Univ. Medical Ctr. (Netherlands)
Judith R. Kroep, Leiden Univ. Medical Ctr. (Netherlands)
Boudewijn P. F. Lelieveldt, Leiden Univ. Medical Ctr. (Netherlands)
Gerrit-Jan Liefers, Leiden Univ. Medical Ctr. (Netherlands)
Alan Chan, Leiden Univ. Medical Ctr. (Netherlands)
Percuros B.V. (Netherlands)
Clemens W. G. M. Löwik, Leiden Univ. Medical Ctr. (Netherlands)
Jouke Dijkstra, Leiden Univ. Medical Ctr. (Netherlands)
Cornelis J. H. van de Velde, Leiden Univ. Medical Ctr. (Netherlands)
Martin N. J. M. Wasser, Leiden Univ. Medical Ctr. (Netherlands)
Alexander L. Vahrmeijer, Leiden Univ. Medical Ctr. (Netherlands)

Published in SPIE Proceedings Vol. 9303:
Photonic Therapeutics and Diagnostics XI
Hyun Wook Kang; Brian J. F. Wong; Melissa C. Skala; Bernard Choi; Guillermo J. Tearney; Andreas Mandelis; Nikiforos Kollias; Kenton W. Gregory; Mark W. Dewhirst; Justus F. Ilgner; Alfred Nuttal; Haishan Zeng; Laura Marcu; Claus-Peter Richter, Editor(s)

© SPIE. Terms of Use
Back to Top